Posted by Michael Wonder on 16 Nov 2020
Eisai receives approval for indication expansion of anti-epileptic agent Fycompa for use in paediatric patients
16 November 2020 - Eisai announced that it has been received approval from the European Commission for the use of its in-house discovered and developed anti-epileptic agent Fycompa (perampanel) in the treatment of paediatric patients.
This approval extends the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalisation) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalised tonic-clonic seizures from 12 years and above to 7 years and above.
